ADC Therapeutics SA ADCT
ADC Therapeutics SA (NYSE: ADCT) is an oncology drug developer. Its lead program, ZYNLONTA (loncastuximab tesirine-lpyl), is in Phase 3 for relapsed/refractory DLBCL after two or more lines of systemic therapy. Its next catalyst on record is ZYNLONTA (loncastuximab tesirine-lpyl): Company announces LOTIS-7 and MZL data abstracts expected in early November with presentations in December at ASH. (November 2026).
Upcoming catalysts
- November 2026ZYNLONTA (loncastuximab tesirine-lpyl) — Company announces LOTIS-7 and MZL data abstracts expected in early November with presentations in December at ASH.
These efforts extend our expected cash runway and increase strategic optionality, as we approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting.
- November 2026loncastuximab tesirine (ZYNLONTA) — Company expects LOTIS-7 and marginal zone lymphoma data abstracts in early November with presentations in December at ASH.
We approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting.
Next further out: ZYNLONTA (MZL IIT) — Presentation of updated MZL data (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZYNLONTA monotherapy (3L+ DLBCL) | r/r DLBCL, 3L+ | antibody | Approved |
| ZYNLONTA + rituximab (LOTIS-5) | r/r DLBCL, 2L+ | antibody | Phase 3 |
| ZYNLONTA + rituximab (IIT) | r/r follicular lymphoma | antibody | Phase 2 |
| ZYNLONTA monotherapy (IIT) | marginal zone lymphoma | antibody | Phase 2 |
| ZYNLONTA + glofitamab (LOTIS-7) | r/r DLBCL | antibody | Phase 1 |
| ADCT-241 (PSMA-targeting exatecan ADC) | prostate cancer (PSMA) | antibody | Pre-clinical |
Recent results and decisions
- Oct 7, 2026n/a ADC Therapeutics announces $86.6 million private placement to extend cash runway into 2029.
ADC Therapeutics has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors, including new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital, in a $86.6 million private investment in public eq
Filing - Oct 7, 2026n/a ADC Therapeutics amends HealthCare Royalty financing agreement, removing change-of-control payment.
HealthCare Royalty financing agreement amended, removing change-of-control payment
Filing - Oct 7, 2026n/a Company amended HealthCare Royalty financing agreement, removing change-of-control payment.
The HCR Amendment amends the warrants to purchase 9,834,776 common shares, which were issued on February 18, 2026, in connection with a previous amendment to the HCR Agreement (the 'HCR Warrants'), by reducing the exercise price of the HCR Warrants from $3.8130 per share to $0.10 per share.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.